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Objectives: The purpose of this study was to determine the pattern of mediastinal
dissemination of nonseminomatous germ cell tumors of testicular origin and eval-
uate variables that may influence survival with mediastinal dissection in patients
with metastatic nonseminomatous germ cell tumors.
Methods: From 1981 to 2000, a total of 421 patients were seen at our institution for
extirpation of residual lung or mediastinal disease after cisplatin-based chemother-
apy for metastatic testicular nonseminomatous germ cell tumors. We reviewed 268
of these patients, with a mean age of 26.8 years, who required at least one surgical
procedure to remove residual mediastinal disease. Pathologic types of resected
residual mediastinal disease were necrosis (15%), teratoma (59%), persistent non-
seminomatous germ cell cancer (15%), and non-germ cell carcinomatous degener-
ation (11%). Twelve variables were evaluated by univariate analyses, and four
variables potentially statistically significant at P  .10 were subsequently entered
into a Cox regression model.
Results: All patients demonstrated metastases to the visceral mediastinum. Fewer
patients also demonstrated metastases to the paravertebral sulcus or anterior com-
partments (16% and 7%, respectively). Overall 5- and 10-year survivals were 86%
 2% and 74%  4%, respectively. According to multivariate analysis, disease-
related survival was negatively influenced by an elevated preoperative -human
chorionic gonadotropin level (P  .028) and adverse pathologic characteristics of
residual mediastinal disease (P  .006).
Conclusions: Testicular nonseminomatous germ cell tumors follow a predictable
pattern of mediastinal dissemination, primarily following the course of the thoracic
duct and its major tributaries. Patients who require surgery to remove residual
mediastinal disease after cisplatin-based chemotherapy for metastatic nonsemino-
matous germ cell tumors have good to excellent long-term survivals. These results
justify an aggressive surgical approach, including multiple surgical procedures if
clinically indicated.
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Nonseminomatous germ cell tumors (NS-GCTs) of testicular origin are the mostcommon neoplasm in male patientsyounger than 40 years.1 It is estimatedthat 8000 new cases will be diagnosed inthe United States each year, with the
worldwide incidence doubling during the past 40 years. In
addition, according to birth cohort data, testicular NSGCT is
being diagnosed at a younger age.2 Despite the increasing
incidence of testicular NSGCT, mortality rates have dra-
matically fallen by an estimated 70% since the advent of
cisplatin-based chemotherapy regimens in the 1970s.3,4 The
paradigm of cisplatin-based chemotherapy followed by sur-
gery to remove residual disease is currently viewed as the
most successful multimodality cancer treatment model, that
against which other solid cancer treatments are compared.
Although hematogenous metastases to the lung, bone, or
brain may occur, testicular NSGCT most frequently metas-
tasizes through the lymphatics to the retroperitoneum and
may subsequently metastasize to contiguous mediastinal
lymphatics. Cisplatin-based chemotherapy alone suffices
for a cure for most patients with supradiaphragmatic metas-
tases. In approximately 10% to 20% of testicular NSGCT
cases with presentation or subsequent development of su-
pradiaphragmatic metastases, at least one thoracic surgical
procedure, in the form of either mediastinal dissection or
pulmonary metastasectomy, is required to remove persistent
radiographic abnormalities after chemotherapy.5 Few stud-
ies have reported clinical outcomes of this select population
with testicular NSGCT treated with surgery to remove re-
sidual intrathoracic disease.6-9 These reports have mainly
focused on patients undergoing pulmonary metastasectomy
for hematogenous metastases. The purpose of this retro-
spective study was to determine the patterns of mediastinal
dissemination, determine outcomes with resection of medi-
astinal metastases, and analyze variables that may influence
long-term survival with mediastinal dissection in patients
with testicular NSGCT.
Material and Methods
Patient Identification and Variables
Institutional records of 421 patients with the diagnosis of testicular
NSGCT who underwent removal of residual intrathoracic disease
after cisplatin-based chemotherapy between 1980 and 2000 were
reviewed to select the subset of patients who had undergone at
least one surgical procedure to remove residual mediastinal dis-
ease. The following variables were recorded when available: age at
diagnosis, date of diagnosis, serum tumor marker (STM, -feto-
protein [AFP] and the  subunit of human chorionic gonadotropin
[hCG]) levels at diagnosis and at surgery, stage at presentation (I,
testes; II, retroperitoneum; III, supradiaphragmatic; III advanced,
liver, brain, or bone metastases), the presence of pulmonary me-
tastases, testicular pathologic type, the need for second-line che-
motherapy before surgery, the number and surgical approaches to
remove residual intrathoracic disease, the need for concomitant or
separate retroperitoneal lymph node dissection (RPLND) and
modified neck lymph node dissection (MND), the location of
mediastinal metastases (anterior compartment; paravertebral sul-
cus; and middle or visceral compartment, which was subdivided
into three additional compartments, upper middle, thoracic inlet to
tracheal carina, mid middle, tracheal carina to dome of the dia-
phragm, and lower middle or retrocrural, dome of diaphragm to
crus), the need to remove adjacent intrathoracic organs or pulmo-
nary metastases, “worst” pathologic category of all residual me-
diastinal disease (necrosis, no viable tumor; teratoma, mature or
immature teratoma; persistent NSGCT; non-germ cell cancer, de-
generation into sarcoma, primitive neuroectodermal tumor, and
adenocarcinoma), and postoperative morbidity or mortality.10
Indications and Techniques of Mediastinal Surgery
Indications for surgery were based on multiple factors, including
disease stage at presentation, the serologic and radiographic re-
sponse to chemotherapy, and the pathologic findings of RPLND if
performed.11 Moreover, rarely were efforts made to obtain either a
tissue or cytologic diagnosis before surgery, because benign and
malignant pathologic types of residual or recurrent mediastinal
masses were typically predicted by clinical and radiographic find-
ings. In general, after completion of cisplatin-based chemotherapy,
patients underwent restaging with STMs and computed tomo-
graphic (CT) body scans. Most patients had normalization of
previously elevated STMs and either a significant reduction or
resolution of all radiographic evidence of disease in the retroperi-
toneum and chest. Patients with demonstrated progression of dis-
ease during or soon after first-line chemotherapy were given sec-
ond-line platin-based chemotherapy (eg, vinblastine, ifosfamide,
and cisplatin, or high-dose platin-based chemotherapy with autol-
ogous stem cell rescue). If significant radiographic abnormalities
remained in the retroperitoneum and chest, then RPLND was
typically performed first. If RPLND pathologic examination dem-
onstrated elements of persistent NSGCT, then second-line chemo-
therapy was usually administered before removal of residual me-
diastinal disease. Because there is a high correlation between the
pathologic findings of tumor necrosis in residual retroperitoneal
and intrathoracic masses after successful first-line chemotherapy,
we would usually radiographically observe persistent mediastinal
abnormalities if necrosis alone was found in the RPLND speci-
men.12 If more extensive residual mediastinal disease was present
after second-line chemotherapy, then mediastinal dissection was
performed even if RPLND pathologic examination demonstrated
tumor necrosis as bulky areas of residual necrosis that might
contain viable cells with future growth or malignant degeneration
potential that would be refractory to further chemotherapy. Bulky
residual mediastinal masses suspected of containing tumor necro-
sis not infrequently represent situations where dissection is tech-
nically difficult because of obscured tissue planes. Adjacent and
even adherent intrathoracic organs, such as the great arteries,
trachea, and esophagus, were typically spared, however, to avoid
morbidity. Thoracic surgery was mainly performed for residual
low-density cystic mediastinal masses suspected of containing
teratoma, either after recovery from chemotherapy or when iden-
tified during follow-up. Given the high potential for cure as well as
the ability to more readily dissect teratomatous masses from major
intrathoracic organs and nerves without sacrifice, surgery was
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indicated regardless of the extent of residual mediastinal disease in
this setting. Salvage thoracic surgery was performed for persistent
NSGCT (usually signified by significant STM elevation) after
second-line chemotherapy or for degeneration into non-germ cell
cancer, both situations that are typically refractory to additional
chemotherapy. Surgery was performed as a salvage strategy only
in patients with radiologic evidence of limited mediastinal disease,
either after recovery from second-line chemotherapy or when
malignant mediastinal disease was seen during follow-up. More-
over, a more aggressive surgical approach was not infrequently
necessary, with removal and if necessary reconstruction of adher-
ent or frankly involved adjacent organs or great vessels. In further
contrast to resections of teratomatous masses, intraoperative fro-
zen-section analysis was used to assess surgical margins after
removal of chemorefractory disease.
Specific surgical approaches for all mediastinal compartments
harboring residual disease were selected to minimize of the overall
number of thoracic procedures necessary while optimizing expo-
sure to remove residual disease.11 Moreover, to reduce the overall
number of surgical procedures, one thoracic surgical procedure
was not infrequently performed in conjunction with RPLND or
MND. In summary, residual disease in the upper middle medias-
tinum (and anterior mediastinum when present) was approached
through a median sternotomy. If extension of residual disease into
the thoracic inlet was present or concomitant MND was per-
formed, then a cervicosternotomy approach was used. With upper
middle mediastinal disease limited to the upper and lower para-
tracheal spaces, a standard right-sided posterolateral thoracotomy
through the 4th or 5th intercostal space was performed. For iso-
lated mid middle mediastinal disease, a standard right-sided pos-
terolateral thoracotomy through the 5th or 6th intercostal space
was used. Lower middle mediastinal disease, if isolated, was
approached through an oblique thoracotomy over the 7th or 8th
ribs or through a thoracoabdominal or transabdominal approach in
conjunction with RPLND if contiguous with retroperitoneal
lymphadenopathy. If both RPLND and mediastinal dissection in-
volved nonbulky and noncontiguous disease, then both RPLND
and mediastinal dissection were commonly performed during the
same anesthetic period through separate abdominal and thoracic
incisions.5 Because most patients received bleomycin as part of
first-line cisplatin-based chemotherapy regimens, perioperative
fluid administration and inspired oxygen concentrations were min-
imized.
Follow-up and Statistical Analysis
After successful removal of all residual intrathoracic disease, pa-
tients demonstrating tumor necrosis, persistent NSGCT, or non-
germ cell cancer were followed up with serial STM measurements
and routine chest radiographs. If persistent NSGCT elements were
present in residual mediastinal disease removed after first-line
chemotherapy, then two additional courses of cisplatin combina-
tion chemotherapy were usually administered. Patients with dem-
onstrating pathologic evidence of teratoma were also followed up
with serial CT body scans. Any new mediastinal or lung abnor-
malities detected during long-term follow-up were removed ac-
cording to the previous indication criteria. Referring physicians
were contacted if there was no institutional record of follow-up
within 6 months of review. Patients were categorized as alive and
well, alive with disease, dead of disease, dead of non-disease-
related causes, or unavailable follow-up.
Kaplan-Meier analysis was used to calculate overall survival,
survival by pathologic category, and disease-free survival from the
time of diagnosis. All variables potentially predictive of long-term
survival were evaluated by Cox regression to establish hazard
ratios. Variables that were found to be predictive of survival with
a P value less than .1 were entered into a multivariate analysis
model with Cox regression to identify a subset of variables that
were independently predictive of survival.
Results
There were 268 patients found who underwent at least one
surgical procedure to remove residual disease in the medi-
astinum after chemotherapy. The remaining 153 patients
underwent surgery to remove pulmonary metastases only
and were therefore excluded from review. The mean age
was 26.8  7.6 years (range 12-58 years). These patients
underwent a total of 455 procedures to remove intrathoracic
disease from 4 to 251 months from the time of diagnosis
(median 12 months). One hundred forty-two patients
(53.0%) underwent one procedure, 80 patients (29.9%) un-
derwent two procedures, 35 (13%) underwent three proce-
dures, and 11 patients (4.1%) underwent four to six proce-
TABLE 1. Patient demographic characteristics and disease
profile at time of diagnosis
Variable No. %
Race (n  268)
White 250 93.3
Other 18 6.7
AFP (ng/mL, n  227)
0-25 42 18.5
26-100 29 12.8
101-1000 59 25.9
1001-10,000 78 34.4
10,000 19 8.4
hCG (ng/mL, n  233)
0-1.5 45 19.3
1.6-1000 94 40.3
1001-50,000 64 27.5
50,000 30 12.9
Stage (n  258)
I (testes) 24 9.3
II (retroperitoneum) 46 17.8
III (above diaphragm) 170 65.9
III advanced (liver, bone, brain) 18 7.0
Lung metastases (n  192)
Present 118 61.5
Absent 74 38.5
Testicular pathology (n  265)
Seminoma 64 24.2
Yolk sac 84 31.7
Embryonal 184 69.4
Choriocarcinoma 44 16.6
Teratoma 189 71.3
Other 66 24.9
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dures. Ninety-eight percent of patients (n  210/215)
demonstrated elevated STM levels at diagnosis, with near
equal frequencies of AFP (n  185/227, 81.5%) and hCG
(n  188/233, 80.7%) elevation (Table 1). All patients had
a component of NSGCT cancer found in the testicular
pathologic examination, with most (69.4%) demonstrating
embryonal cell carcinoma, 21.3% demonstrating elements
of teratoma, and 24.2% demonstrating seminomatous germ
cell cancer. Most patients (n  170, 65.9%) were seen with
supradiaphragmatic (stage III) disease; however, the other
98 patients manifested mediastinal disease either during or
after cisplatin-based chemotherapy. Ninety-four (35.1%)
patients received second-line chemotherapy before removal
of residual intrathoracic disease. Before all surgical proce-
dures, 176 patients (68.4%) had normalization of STM
levels. The other 91 (31.6%) patients underwent surgery
with elevated STM levels, with most of these patients dem-
onstrating minor elevations only (Table 2). Eighty-four
(31.3%) patients underwent MND, 55 of which procedures
(12.1%) were done in conjunction with mediastinal surgery.
The vast majority of patients in this series (239, 89.2%)
underwent RPLND, and 141 thoracic surgical procedures
(31.9%) were performed in conjunction with RPLND.
The distributions of mediastinal metastases and surgical
approaches are shown in Table 3. In summary, all patients
had residual disease removed from the middle mediastinum,
with most (67.5%) undergoing a mid middle mediastinal
dissection (carina to dome of diaphragm). A smaller fraction
of patients also had disease removed in the paravertebral
sulcus and anterior mediastinal compartments (15.7% and
7.1%, respectively). Slightly more than half of these proce-
dures (51.2%) were carried out through a posterolateral
thoracotomy approach, and 14.5% were carried out through
a thoracoabdominal approach in conjunction with RPLND.
Eighty-one patients underwent removal of upper middle
mediastinal disease through a sternotomy, and 60 under-
went a transabdominal approach to remove residual lower
middle mediastinal disease. Fifteen patients (5.6%) with
either persistent NSGCT or non-germ cell cancer required
removal of a major vascular structure (n  12), superior
vena cava or brachiocephalic vein (n  6), subclavian or
carotid artery (n  3), descending thoracic aorta (n  3), or
a significant portion of the esophageal muscular wall (n 
3). Seven patients underwent separate thoracoscopy proce-
dures to remove peripheral pulmonary metastases only.
Some form of pulmonary resection was required to remove
intrapulmonary or hilar disease in a total of 128 cases
(47.8%). Pulmonary wedge resections were most commonly
performed, with 109 patients (40.7%) undergoing medias-
tinal dissection and 38 patients (14.1%) and 10 patients
(3.7%) requiring lobectomy and pneumonectomy, respec-
tively.
Operative morbidity and mortality were low among these
otherwise young and healthy male patients. There were 3
operative deaths (1.1% of patients). Two patients died of
adult respiratory distress syndrome after lobectomy and
pneumonectomy for extensive residual middle mediastinal
and hilar disease. Both of these patients had only necrosis in
the resected specimens. One patient died of complications
related to gastric perforation after a combined thoracoab-
dominal approach to remove residual teratoma. Thirty-two
(11.9%) patients had nonfatal postoperative complications,
including the following: pneumonia, significant atelectasis,
or more than 48 hours of mechanical ventilation (n  9);
TABLE 2. Preoperative STM status
Variable No. %
STMs (n  257)
Normal 176 68.4
Elevated 91 31.6
AFP (ng/mL, n  257)
0-25 216 84.0
26-100 20 7.8
101-1000 11 4.2
1001-10,000 10 4.0
10,000 0 0.0
hCG (ng/mL, n  257)
0-1.5 213 82.9
1.6-1000 44 17.1
1001-50,000 0 0.0
50,000 0 0.0
Levels reported represent the highest values before removal of any in-
trathoracic disease.
TABLE 3. Anatomic distribution of residual mediastinal
disease and surgical approach
Variable No. %
Anatomic location
Anterior 19 7.1
Middle or “visceral” 268 100.0
Upper 119 44.4
Mid 181 67.5
Lower 125 46.6
Paravertebral sulcus 42 15.7
Surgical approach
Thoracotomy
Right 128 28.1
Left 110 24.1
Thoracoabdominal
Right 39 8.1
Left 27 5.9
Transabdominal 60 13.2
Clam shell 3 0.6
Sternotomy 81 17.8
Thoracoscopy 7 1.5
Percentage of mediastinal compartment is expressed as a fraction of the
total number of patients undergoing mediastinal dissection (n  268).
Percentage of surgical approaches is expressed as a fraction of the total
number of intrathoracic surgical procedures (n  455).
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chylothorax persistent for longer than 10 days (n  8); air
leakage prolonged for longer than 10 days (n 8); bleeding
necessitating reoperation (n  4); atrial arrhythmias (n 
3); pleural space infection (n  3); recurrent nerve palsy
(n  2); and pulmonary embolism (n  2). Of significant
note, 6 patients manifested postoperative lower extremity
paresis or paraplegia after circumferential lower descending
thoracic aorta dissection to remove residual masses contain-
ing teratoma. Of these patients, 4 demonstrated significant
improvement of neurologic function and 2 did not.
At last follow-up 200 patients were alive, and 169 were
both alive and free of disease. Fifty-seven patients had died
(47 of the disease, 7 of other or unknown causes, and 3 of
operative causes as previously described). Sixteen patients
are unavailable for follow-up. The overall 5- and 10-year
survivals were 86%  2% and 74%  4%, respectively
(Figure 1). The overall 5- and 10-year disease-free survivals
were 80%  3% and 63%  4%, respectively. The worst
pathologic classification of residual mediastinal disease was
necrosis in 14.9% (n  39), teratoma in 58.8% (n  154),
persistent NSGCT in 15.6% (n  41), and non-germ cell
cancer in 10.7% (n  28). The pathologic finding of com-
plete tumor necrosis in residual mediastinal disease pre-
dicted excellent survival (mean 190  11 months), which
was statistically superior to that associated with non-germ
cell cancer (mean 123  20 months, P  .007) but not
statistically significantly different from those of the other
two pathologic categories of teratoma (mean 181 10, P
0.196) and persistent NSGCT (mean 202  23, P  .147;
Figure 2) The finding of teratoma in residual mass patho-
logic examination also predicted better survival than did
that of non-germ cell cancer (P  .008) but not that of
persistent NSGCT (P  .80). The subset of patients with
pathologically demonstrated either tumor necrosis or tera-
toma had an overall 78.3%  4.4% 10-year survival. Dis-
ease-free survival according to worst mediastinal pathologic
class is shown in Figure 3. Patients with tumor necrosis
demonstrated superior mean survival (115  7 months),
which was again statistically better than that of patients with
non-germ cell cancer (79  10 months, P  .001) and also
significantly better than that of patients with persistent NS-
GCT (106  6 months, P  0.042). Mean disease-free
survival of patients with teratoma (105 4 months) was not
statistically different from that of patients with necrosis
(P  .189), however. Finally, residual mass pathologic type
of teratoma predicted better statistical disease-free survival
than did that of non-germ cell cancer (P .001) but not that
of persistent NSGCT (P  .268).
The univariate analysis of 12 variables that potentially
could influence survival is depicted in Table 4. Other than
adverse pathologic type of residual mediastinal disease, an
older age at diagnosis appeared to have a significantly
negative impact on survival (P  .014). There were 15
patients older than 40 years at the time of diagnosis, and 7
(46.7%) of these patients have died (2 of disease, 1 of
operative causes, and 4 of non-cancer-related causes or
unknown causes). In contrast, there were 14 patients
younger than 14 years of age with only 2 late deaths, both
Figure 1. Long-term overall and disease-free survivals for 268 patients who underwent postchemotherapy resection
of residual mediastinal disease. Numbers represent patients at risk at 2.5-year increments. See text for details.
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attributable to disease. There was a trend toward elevation
in either STM level at the time of surgery predicting dimin-
ished survival (P  .115), and an elevated preoperative
hCG did reach statistical significance in this regard (P 
.036). In contrast, however, an elevated AFP at time of
surgery was not predictive (P  .760). There were 44
patients who had elevated hCG levels at time of surgery,
and 16 of these patients (36.4%) have died (15 of disease
and 1 of non-cancer-related causes). The need for separate
removal of residual pulmonary disease after chemotherapy
was not predictive of an adverse outcome (P  .764);
however, removal of residual lung disease containing either
persistent NSGCT or non-germ cell cancer was predictive
by univariate analysis (P  .012). Finally, in a Cox regres-
sion model, older age at diagnosis (P  0.005), elevated
hCG level at surgery (P  .028), and more serious patho-
logic class of residual mediastinal disease (P  .006) were
the only variables found to be independently predictive of
poorer long-term survival.
Discussion
Intrathoracic NSGCTs, whether primary mediastinal NS-
GCTs (PMNSGCTs) or, more commonly, NSGCTs meta-
static to the mediastinum from the testes, provide unique
and interesting biologic tumor models. Elevated STM levels
usually correlate with the presence of viable NSGCT. There
is distinctly better survival after excision of residual disease
metastatic to the mediastinum from testicular NSGCT than
with PMNSGCT, however. We found an 86% 5-year sur-
vival in this series, as compared with a 56% survival after
chemotherapy and surgery for PMNSGCT, which clearly
demonstrates their different biologic behaviors despite sim-
ilar histologic characteristics.13 Chemotherapy in our previ-
ously reported PMNSGCT series converted active NSGCT
to either necrosis or teratoma in 59% of cases.13 In contrast,
these current data demonstrate that cisplatin-based regimens
converted mediastinal metastases from NSGCT of testicular
origin into necrosis or teratoma histologic type in 74% of
surgical cases. The difference in the biologic response to
chemotherapy is further amplified by the fact that the vast
majority of all residual masses in patients with PMNSGCT
are resected after chemotherapy, as opposed to only a mi-
nority of residual mediastinal masses suspected of contain-
ing necrosis in patients with testicular NSGCT.12 Moreover,
patients with testicular NSGCT who show evidence of
persistent NSGCT in residual mediastinal disease also ap-
pear to have a better long-term survival after salvage sur-
gery, with a mean survival of 202 months, as opposed to a
mean survival of only 52 months after salvage surgery for
PMNSGCT. Regardless of the site of origin, the curability
of NSGCTs establishes these diseases as models of success-
ful multimodality therapy after which treatments of other
intrathoracic and extrathoracic solid human cancers are pat-
terned.
Figure 2. Long-term survival according to worst postchemotherapy pathologic category. Numbers represent
patients at risk at 2.5-year increments. See text for details.
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In addition, PMNSGCT originates in the anterior medi-
astinal thymic tissues. Mediastinal metastases from NSGCT
of testicular origin, however, appear to follow a predictable
pattern of dissemination mainly along the distribution of the
thoracic duct and its major lymphatic tributaries. We favor
using the mediastinal compartments described by Shields,10
who designates the middle mediastinum as consisting of the
visceral mediastinum from the thoracic inlet to the dia-
phragmatic crura. In this designation, the middle mediasti-
num includes not only the ascending and aortic arch, bra-
chiocephalic vessels, and esophagus superiorly, but the
descending thoracic aorta, adjacent azygos vein, and esoph-
agus to the diaphragmatic crura inferiorly. This designation
is more logical from embryologic, anatomic, and pathologic
standpoints with respect to keeping all the major lymphatic
vessels within the middle mediastinum than is the more
frequently used designation in which major arteries and
adjacent lymphatics course through at least two of the
mediastinal compartments with somewhat arbitrary bound-
aries.14 Moreover, subdividing the middle or visceral medi-
astinum into roughly equal thirds (upper, mid, and lower)
dictates optimal surgical approaches to remove residual
intrathoracic disease.11 Although the residual disease ap-
pears to rather uniformly disseminate throughout the major
lymphatics of the middle or visceral mediastinum, occasion-
ally metastases are also present in the anterior compartment
and paravertebral sulcus, presumably as a result of branch
lymphatic spread probably contributed by malignant ob-
struction of more cephalic lymphatic vessels. We found,
however, no cases of isolated metastases in the anterior
mediastinal compartment or paravertebral sulcus without
Figure 3. Long-term disease-free survival according to worst postchemotherapy pathologic category. Numbers
represent patients at risk at 2.5-year increments. See text for details.
TABLE 4. Univariate analysis of survival
Variable
Hazard
ratio
95% Confidence
interval
P
value
Age at diagnosis 1.04 1.01-1.08 .014
AFP at diagnosis 1.09 0.85-1.38 .507
hCG at diagnosis 0.76 0.55-1.06 .102
Stage at diagnosis 1.10 0.77-1.57 .618
Teratoma (testes) 1.22 0.68-2.17 .507
Normal STMs at surgery 0.65 0.38-1.11 .115
AFP at surgery 0.95 0.68-1.32 .760
hCG at surgery 1.86 1.04-3.31 .036
Residual lung disease
removed
1.08 0.64-1.83 .764
Malignant lung disease
removed
2.11 1.18-3.77 .012
Malignant mediastinal
disease removed
1.69 0.98-2.91 .060
Pathologic type of
mediastinal disease
1.55 1.14-2.12 .006
STM, AFP, and HCG levels at surgery represent the highest values before
removal of any intrathoracic disease. Residual lung disease removed
refers to cases in which separate pulmonary resection was required, and
malignant lung disease or mediastinal disease removed refers to removal
of either persistent NSGCT or non-germ cell cancer.
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middle mediastinal metastases. NSGCT isolated to the an-
terior compartment in a patient with a history of testicular
NSGCT should therefore be considered a second primary
neoplasm.
Operative morbidity and mortality were low among these
otherwise young and healthy male patients, particularly as
mediastinal dissection usually did not require removal of
major intrathoracic organs or nerves. Bleomycin, commonly
used with cisplatin and etoposide in combination therapy for
the treatment of metastatic NSGCT, is known to cause
pulmonary fibrosis and an associated reduction in diffusing
capacity. Bleomycin is typically administered to a maxi-
mum of 360 units. Unfortunately, this may have contributed
to 2 of the 3 postoperative deaths that followed anatomic
pulmonary resections. Although teratoma can usually be
dissected from adjacent major hilar airways and blood ves-
sels, tumor necrosis, persistent NSGCT, and non-germ cell
cancer often cannot be readily dissected from adjacent
structures. In cases in which anatomic pulmonary resection
may be necessary, we are currently limiting the total bleo-
mycin dose to 300 units. Most of our non-fatal complica-
tions were also pulmonary in nature. Further study is indi-
cated to clarify bleomycin-related morbidity and mortality
and to determine optimal bleomycin dose, particularly when
large pulmonary resection is anticipated. Of significant note
was the complication of lower extremity paresis or paraple-
gia, which occurred in our series after circumferential tho-
racic aortic dissection in the lower middle mediastinum
(retrocrural) compartment for removal of residual terato-
ma.15 This complication fortunately did not occur in the 3
patients who underwent descending thoracic aortic removal
and prosthetic vascular graft replacement; however, those
patients were also at risk. Although it is technically chal-
lenging, to avoid the risk of spinal cord ischemia we are
currently attempting to spare larger diameter intercostal
arteries in this compartment when anatomically and onco-
logically feasible. Certainly, appropriate preoperative coun-
seling regarding the potential for neurologic complications
is warranted if circumferential lower descending thoracic
aortic dissection or resection is planned that would result in
the sacrifice of any pair (or pairs) of intercostal arteries
during tumor removal.
Long-term survival was found to be excellent with re-
moval of residual mediastinal disease, particularly if the
pathologic class was necrosis or teratoma. This finding
justifies an aggressive thoracic surgical approach in these
cases, which not infrequently require multiple surgical pro-
cedures to remove bilateral residual disease or disease that
appears during subsequent radiographic follow-up. Pro-
longed survival also appears possible with resection of
limited areas of persistent NSGCT or non-germ cell cancer
within the mediastinum. There have been few previous
reports on the outcomes of patients with testicular NSGCT
with resection of residual intrathoracic disease after cispla-
tin-based chemotherapy. Liu and colleagues8 reported on
143 patients with testicular NSGCT with hematogenous
metastasis to the lung who underwent pulmonary metasta-
sectomy with 71% 5-year survival. Cagini and colleagues9
and Anyanwu and associates6 also published series consist-
ing primarily of patients with testicular NSGCT who un-
derwent pulmonary metastasectomy, reporting 5-year sur-
vivals of 77% and 59%, respectively. Although previous
reported survival has been excellent for stage III (supradi-
aphragmatic) disease, it does appear to be somewhat inferior
to our overall survival of 86% at 5 years for patients with
stage III disease undergoing surgery to primarily remove
residual disease disseminated from the retroperitoneum into
the mediastinal lymphatic tissues.
Multivariate analysis found elevated preoperative hCG
levels, pathologic status of residual mediastinal disease, and
older age at the time of diagnosis as independent risk factors
for poor long-term outcome. Elevated hCG level usually
signifies the presence of persistent choriocarcinoma or em-
bryonal cell carcinoma in residual disease and has been
previously reported to have a significantly negative impact
relative to elevated preoperative AFP levels on survival
before RPLND.16,17 Adverse pathologic status, which in-
cludes persistent NSGCT or non-germ cell cancer, has also
been previously reported to adversely affect long-term sur-
vival in patients with NSGCT with intrathoracic metastases
after surgery.6,8,9 The presence of either persistent NSGCT
or non-germ cell cancer in the mediastinum is not infre-
quently suspected before surgery on the basis of multiple
variables, including CT characteristics of more solid (versus
low-density cystic) areas, high preoperative STM levels,
late relapse, or history of other areas from the retroperito-
neum or neck having been removed and found to harbor
malignant pathologic processes. Our 10-year survival data
for these poor-risk patients also demonstrate that long-term
survival is possible when surgical candidates with limited
malignant mediastinal disease are carefully chosen. Patients
who sustained a late relapse with masses not infrequently
containing chemotherapy-refractory pathologic processes,
such as persistent NSGCT or non-germ cell cancer, also
underscore the need for longer (5 year) disease-free sur-
vival analysis. Finally, age has not previously been found to
be an independent risk factor for long-term survival after
treatment for metastatic NSGCT of testicular origin. In the
subgroup of patients at least 40 years old, 5 of the 7 patients
who died had either operative, late non-cancer-related, or
late unknown causes of death, which may have erroneously
skewed statistical analysis of this variable, at least with
respect to disease-related survival. Certainly, patients with
disease diagnosed at or after the age of 40 years would be
expected to be at greater risk for non-cancer-related death
after long-term follow-up than would younger patients.
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Although many patients with a diagnosis of NSGCT of
testicular origin are first seen with stage III disease, only a
minority ultimately require surgical removal of residual
mediastinal disease after cisplatin-based chemotherapy. Pa-
tients who do undergo mediastinal dissection have residual
disease distributed throughout the lower, mid, or upper
middle or visceral mediastinum from the thoracic inlet to
the diaphragmatic crura, with residual disease in the mid
middle mediastinum being most common. Residual disease
in the paravertebral sulcus and anterior mediastinal com-
partment occurs much less frequently. Long-term survival
of patients who demonstrate either necrosis or teratoma in
residual mediastinal disease is excellent, which clearly jus-
tifies an aggressive surgical approach, even when extensive
mediastinal or circumferential descending thoracic aortic
involvement is present. Bilateral or multiple thoracic surgi-
cal procedures are not infrequently necessary. Operative
morbidity and mortality are low because sparing of adjacent
organs and nerves is usually possible, particularly with
residual teratomatous disease. As a referral center for tes-
ticular NSGCT cases, we continue to evaluate an increasing
number of patients with chemotherapy-refractory disease.
Salvage operations to remove mediastinal disease in these
cases represent situations in which significantly poorer
long-term survival is anticipated; however, an aggressive
surgical approach is justified for selected patients.
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Discussion
Dr Joe B. Putnam, Jr (Houston, Tex). Kesler and colleagues
have carefully presented a retrospective review of 268 patients
with mediastinal metastases from testicular NSGCT. This article
focuses on metastatic NSGCT rather than PMNSGCT or combined
PMNSGCT and metastatic NSGCT. These patients underwent a
successful combined multimodality approach with chemotherapy
followed by multiple resections. Univariate analysis of suspected
prognostic factors and then Cox regression analysis of significant
factors was undertaken. Kesler and colleagues demonstrated ex-
cellent long-term survival in patients receiving this multimodality
therapy. However, patients who were older or those with elevated
preoperative hCG or adverse pathologic class within the residual
mediastinal disease (eg, nonseminomatous germ cell cancer) had
significantly reduced survival.
I have several questions for Dr Kesler. First, was an attempt at
diagnosis made before the initiation of therapy, and how were such
diagnoses obtained during the 20-year study period? Second, were
there any unusual characteristics of the patients with non-germ cell
cancer? Should these patients undergo biopsy before resection, or
should different chemotherapy be used before or after resection if
such a diagnosis is made? Third, significant neurologic complica-
tions occurred in patients undergoing extensive circumferential
lower descending thoracic aortic dissection. I presume that extra-
corporeal support was routine. Should these patients be excluded
from resection or have the resection modified? Finally, patients
with metastatic NSGCTs have complicated courses, and multiple
combined medical and surgical treatments are required for a suc-
cessful outcome. Should these patients be treated at centers with
experience in this type of surgery, or can they be appropriately
treated at most general hospitals?
Dr Kesler. Most of these patients have their cancer diagnosed
at the time of orchiectomy and initially staged with abdominal,
pelvic, and chest CT scans only. Clinical parameters, such as
serum tumor marker status, CT appearance (low-density cystic vs
solid) and histologic class of RPLND residual disease can usually
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predict mediastinal pathologic type after chemotherapy. In routine
cases, STM levels normalize after first-line chemotherapy and
disease is restaged with repeated CT scans. Any residual low-
density cystic masses within the mediastinum almost always rep-
resent teratoma and are surgically treated with a conservative type
of resection without the need for either prechemotherapy or
postchemotherapy biopsy. For less common situations in which
patients have serologic or CT evidence of chemorefractory disease
in the mediastinum, such as persistently elevated STM levels after
second-line chemotherapy or after late relapse, we more frequently
use combined CT and positron-emission tomographic scanning as
opposed to biopsy, because this will accurately localize disease as
well as assure us that there only is a limited amount of disease (one
or two areas) present before surgery. In addition, surgery is typi-
cally done with frozen-section analysis of the surgical margin in
these chemorefractory cases. In summary, we only rarely encoun-
ter situations in which open or fine-needle aspiration biopsy of a
mediastinal mass in a patient with a history of testicular NSGCT
would change recommendations for surgical removal. The patho-
logic type of residual disease may, however, determine the degree
of surgical aggressiveness.
Neurologic injury did occasionally occur after circumferential
removal of teratoma surrounding the lower descending thoracic
aorta. Fortunately, this complication usually resulted in some
degree of paraparesis, as opposed to frank paraplegia. We attribute
this complication to division of the paired intercostal arteries
during circumferential aortic dissection, which does not require
circulatory support or aortic occlusion. Somewhat ironically, neu-
rologic injury did not occur in 3 patients undergoing radical
mediastinal dissections, including en bloc removal of the descend-
ing thoracic aorta for isolated areas of primitive neuroectodermal
tumor degeneration. These latter operations were performed with
aortic occlusion and left atrial to left femoral artery heparin-coated
bypass pump circuits. Despite the potential for neurologic morbid-
ity, we still recommend and do not hesitate to perform surgery
after appropriate preoperative consultation for these otherwise
young and healthy patients who have good to fair potential for cure
only with surgical therapy. During circumferential removal of
teratoma surrounding the descending thoracic aorta, we do make
every effort to spare any intercostal arteries encountered during the
dissection in an attempt to minimize the risk of neurologic com-
plications. We unfortunately, however, have not found sparing any
intercostal arteries that course directly through teratomatous
masses to be technically feasible.
Similar to any other solid human cancer, the best results are
usually going to be found at centers that treat large numbers of
patients. Having said that, though, there is certainly no reason that
a surgeon who is familiar with mediastinal anatomy and medias-
tinal surgical techniques could not successfully remove a terato-
matous residual mass in the mid middle mediastinum along the
distribution of the thoracic duct, which our data demonstrate to be
the most frequently encountered scenario. Cases in which residual
teratoma is dispersed throughout the upper middle mediastinum
after chemotherapy are more technically demanding, and careful
attention must be paid to sparing great vessels and intrathoracic
nerves to avoid long-term morbidity in these young patients. Our
specific surgical techniques to remove residual mediastinal disease
from metastatic testicular NSGCT will be presented in a future
edition of The Surgical Clinics of North America.
Dr W. Roy Smythe (Houston, Tex). Dr Kesler, thank you for
allowing us to learn from your unparalleled experience with this
disease. I have a couple of questions. First, I noticed that one of
your independent predictors of bad outcome was the presence of
elevated STM levels at the time of resection. Has this changed
your approach in patients with elevated STM levels? Do you now
send the patients back to the medical oncologists for consideration
of additional chemotherapy if STM levels are still elevated when
patients are being considered for surgical resection? Second, many
of these patients have concomitant parenchymal pulmonary me-
tastasis along with their mediastinal disease. How does the pres-
ence of residual parenchymal metastasis affect your decision
whether to operate on these patients?
Dr Kesler. Unlike treatment of PMNSGCT, in which we
believe that second-line chemotherapy has at best a limited role,
second-line chemotherapy for metastatic NSGCT of testicular or-
igin, in the form of high-dose platin-based chemotherapy with
stem cell rescue, can achieve salvage in as many as 50% of patients
with failure of first-line chemotherapy. Even with aggressive sec-
ond-line chemotherapy, however, anywhere from 10% to 20% of
patients will continue to have STM level elevation, which usually
signifies the presence of persistent testicular NSGCT. These are
cases in which CT and positron-emission tomographic scans may
be helpful to locate the areas of persistent NSGCT. If there are
limited (one or two) areas of mediastinal metastases containing
viable NSGCT amenable to surgical therapy after second-line
chemotherapy, we would offer the patient “salvage surgery” with
a low but real chance of cure. Multiple areas in the mediastinum
(or the lung, for that matter) with persistent NSGCT after high-
dose platin-based chemotherapy with stem cell rescue would un-
fortunately be considered an incurable situation. Degeneration into
sarcomatous or neuroectodermal cancer typically does not increase
STM levels, and it is also refractory to chemotherapy. Again, with
limited areas of mediastinal disease, we believe that surgery offers
the only chance of cure.
Pulmonary metastases from hematogenous spread are common
in this patient population and occurred in nearly half of our
patients with mediastinal metastases. Most of these patients un-
derwent staged bilateral pulmonary metastasectomy procedures
with ipsilateral residual mediastinal disease removed during the
same surgical procedure. Most such patients can be rendered
disease free, particularly if there are only a few peripheral areas of
residual teratomatous disease present. Rare patients with pulmo-
nary nodules too numerous to count would typically have residual
mediastinal disease removed along with larger pulmonary masses
containing teratoma, with parenchymal sparing techniques used if
at all possible. Most residual lung disease would be observed with
serial CT scans, and selected nodules would be removed if growth
was subsequently demonstrated.
Dr Joseph B. Shrager (Philadelphia, Pa). I also found your
presentation particularly interesting, because, like a lot of people in
this room, I occasionally see one of these cases, but not enough to
have a good feel for the disease. These tumors often tend to be
really socked into the mediastinum, and so when one does the
resection, I think one generally finds that one’s margins are close.
Although they may be pathologically negative, you nevertheless
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know that in fact they are very close, and there’s no way to know
that a few cells haven’t been left behind. With the understanding
that these tumors are relatively radioresistant, would you never-
theless ever radiate one of these afterward? Also, is there anything
you do other than limit oxygen for people who have had bleomycin
to try to prevent some of the pulmonary toxicity afterward?
Dr Kesler. As long as postchemotherapy residual disease con-
tains only teratoma, we believe that conservative resection with
removal of all visible disease but without the need for microscopic
surgical margin analysis is completely sufficient. In fact, our main
surgical efforts in these cases are focused on sparing all intratho-
racic vessels and nerves, thereby minimizing morbidity. We be-
lieve that for the most part thoracic radiation therapy has no role in
this disease, with perhaps the very rare exception of sarcomatous
degeneration where surgical extirpation is not possible.
We believe that bleomycin does increase postoperative pulmo-
nary morbidity and subsequent mortality, particularly among pa-
tients who require large anatomic pulmonary resections. We there-
fore try to limit the total bleomycin dose if a large pulmonary
resection is anticipated after combination chemotherapy. Regard-
less of the need for concomitant pulmonary resection, we simply
make efforts to minimize the inspired oxygen concentration and
are judicious with perioperative fluid administration in the case of
any patient who has received this chemotherapy agent before any
thoracic surgical procedure.
Dr Robert J. Ginsberg (Toronto, Ontario, Canada). I have a
couple of questions. As the standard of care at your center for the
primary testicular tumors, you mentioned retroperitoneal node
dissection. Do all your patients undergo retroperitoneal node dis-
section? If they do, do you do synchronous operations? There are
many centers that accept a diagnosis of total necrosis after induc-
tion therapy with normal STM levels and do not do retroperitoneal
node dissections, the “wait and see” policy. Have you ever used
that for the posterior mediastinum or in the middle mediastinum?
Dr Kesler. Nearly 90% of the patients in our series underwent
RPLND at some point, with nearly a third of thoracic surgical
procedures being performed at the same time as RPLND. The high
frequency of retroperitoneal disease in this series is not surprising,
given the lymphatic drainage patterns from the retroperitoneum
directly into the visceral mediastinum through the thoracic duct.
Commonly, if residual masses that are low density and cystic,
typical of residual teratoma, are present in the retroperitoneum and
mediastinum, both RPLND and mediastinal dissection would be
performed during the same general anesthesia. Occasionally a
combined laparotomy and sternotomy approach can actually facil-
itate dissection of retrocrural (low middle mediastinum) disease, as
can left or right thoracoabdominal incisions. If separate abdominal
and thoracic incisions are required, we frequently have our uro-
logic surgeons proceed with RPLND first; if RPLND is uneventful,
we then perform a mediastinal dissection during the same anes-
thetic session. Exceptions to this combination approach include
massive residual retroperitoneal or mediastinal disease that re-
quires extensive and prolonged surgery and the requirement of an
anatomic pulmonary resection. In these cases, removal of intratho-
racic disease is typically performed during a later surgical proce-
dure after satisfactory recovery from RPLND to avoid morbidity,
particularly after bleomycin combination chemotherapy. In con-
trast to PMNSGCT, in which any radiographic abnormality re-
maining after chemotherapy is surgically removed, no matter how
minor or suspicious for complete tumor necrosis the area may be,
we do observe most mediastinal abnormalities after first-line che-
motherapy if the abnormality is solid appearing, STM levels have
normalized, and RPLND pathologic examination has demon-
strated complete necrosis only.
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